Several markers and tests have been introduced in the market for diagnosing cancer types and other diseases. However, most of them either are invasive methods or present very poor diagnostic accuracy as they are based on single markers.
InSyBio’s technology enables the identification of circulating multi-omics markers and bio-signatures in blood and other biofluids while its machine-learning component allows for their combination in multi-markers test, increasing significantly the predictive accuracy. Many successful applications of this technology have been presented and/or published on neurodegenerative and cardiovascular diseases are well as on many cancer types.